A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer

Oesophageal Cancer Clinical Trial

— NeoSCOPE  

Official title:

A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01843829
• Other study ID #: 2012/VCC/0009
• Status: Recruiting
• Phase: Phase 2
• First received: March 7, 2013
• Last updated: March 21, 2014
• Start date: October 2013
• Est. completion date: May 2016

Study information

• Verified date: March 2014
• Source: Velindre NHS Trust
• Contact: Lisette Nixon
• Phone: 02920687458
• Email: nixonls[@]cardiff.ac.uk
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

About 7500 patients are diagnosed with oesophageal cancer each year in the UK of which less than a quarter have resectable disease at diagnosis. There is a general lack of consistency in the standard of care for patients across UK hospitals. Patients are either treated with a) chemotherapy followed by surgical removal of the tumour, or b) chemoradiotherapy followed by removal of the tumour by surgery, as part of their standard of care. Recent research supports the latter treatment, as chemoradiotherapy maybe more effective at shrinking the tumour and preventing the disease from spreading than taking chemotherapy alone. However, there is no definitive way of identifying which treatment is best without a clinical trial.

Evidence suggests that the effect of the chemoradiotherapy currently used as standard practice may be improved and the side effects reduced by using a different chemoradiotherapy combination. In this trial, eligible patients will receive 2 cycles of the same chemotherapy before being randomised to receive two different chemoradiotherapy regimens (carboplatin and paclitaxel verses oxaliplatin and capecitabine) both of which have shown promising results in previous studies. Patients will then have their tumour removed. The best chemoradiotherapy regimen will then be taken forward to a Phase III trial in which chemoradiotherapy will be compared with chemotherapy alone.

The efficacy of the regimens will be measured by counting the number of patients who i) remain free from cancer, ii)have local or distant spread of their cancer, iii) are successfully recruited and iv) experience toxicities. A specific set of toxicity criteria will be used to monitor any treatment induced side-effects and provide justification for any necessary dose modifications or withdrawal of treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 85
• Est. completion date: May 2016
• Est. primary completion date: May 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed operable oesophageal cancer (adenocarcinoma)

• Tumour must be staged as a T3, 4 or N1 (using TNM6 staging) or T3, T4a or N13 using TNM7 staging)

• Maximum disease (Tumour plus nodes) length 8 cm staged with EUS and CT/PET

• WHO performance status 01

• Adequate haematological, renal, respiratory, cardiac and hepatic function

• The patient has provided written informed consent.

Exclusion Criteria:

• Histologically confirmed operable oesophageal cancer (squamous cell carcinoma)

• Uncontrolled angina pectoris, myocardial infarction within 6 months, heart failure, clinically significant uncontrolled cardiac arrhythmias, or any patient with a clinically significant abnormal ECG.

• Patients with any previous treatment for oesophageal carcinoma.

• Siewert type 3 oesophagogastric tumours.

• T4 tumours invading contiguous structures other than diaphragm, crura or mediastinal pleura.

• Patients with disease in any of the following areas on the CT scan, EUS or other staging investigation:

1. Evidence of metastases in liver, lung, bone or other distant metastases.

2. Abdominal para aortic lymphadenopathy >1cm diameter on CT or >6mm diameter on EUS.

3. Invasion of tracheo-bronchial tree, aorta, pericardium or lung.

• Lymphadenopathy encasing the coeliac axis (as described above, patients with single nodes lying anterior to the origin of the splenic artery and anterior to the origin of the coeliac axis are not excluded).

• Any patient with a single significant medical condition which is thought likely to compromise his or her ability to tolerate any of the above therapies.

• Specific contraindications to surgery, chemotherapeutic agents (including known allergies to chemotherapy) or radiotherapy.

• Pregnant or lactating women and fertile women who will not be using adequate contraception during the trial.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Esophageal Neoplasms
• Oesophageal Cancer

Intervention

Drug:
• Oxaliplatin

• Capecitabine

• Carboplatin

• Paclitaxel

Radiation:
• Radiotherapy

Procedure:
• Surgery
Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.

Locations

Country	Name	City	State
United Kingdom	Bristol Oncology and Haematology Centre	Bristol
United Kingdom	Valindre NHS	Cardiff
United Kingdom	University Hospitals Coventry and Warwickshire	Coventry
United Kingdom	Royal Derby Hospital	Derby
United Kingdom	St James's Hospital	Leeds
United Kingdom	Leicester Royal Infirmary	Leicester
United Kingdom	St Mary's Hopsital	London
United Kingdom	The Christie	Manchester
United Kingdom	Churchill Hospital	Oxford
United Kingdom	Weston Park Hospital	Sheffield
United Kingdom	Southampton General Hospital	Southampton
United Kingdom	The Great Western Hospital	Swindon

Sponsors (2)

Lead Sponsor	Collaborator
Lisette Nixon	Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy	The efficacy of the trial treatment will be assessed by conducting analysis on the resected tumour specimen of participants undergoing surgery. This will be achieved by looking at the pathological complete response rate (pCR).	24 months	No
Secondary	Feasibility of recruiting 62 patients within 18 months	Feasibility of recruiting to a pre-operative chemoradiotherapy trial in the UK will be determined by recruitment within 18 months.	18 months	No
Secondary	Safety	The trial safety will be assessed by looking at the toxicity. Toxicities during treatment and at 6 and 12 months post-surgery will be recorded using the CTCAE version 4. SAEs will be collected in real time. The morbidity/mortality rate post surgery will also be assessed.	3 years	Yes
Secondary	Efficacy	The efficacy will be measured as a secondary end point by assessing the median, 3 and 5 year overall survival.	5 years	No
Secondary	Efficacy	The CRM (circumferential resection margin) which is a measurement of how successful the surgery was in removing all traces of tumour, will be assessed.	24 months	No

External Links

•   Wales Cancer Trials Unit website